NL-OMON52411招募中2 期
89Zr-Bevacizumab PET/CT imaging of vestibular schwannomas for the prediction of bevacizumab treatment effect in patients with symptomatic neurofibromatosis type 2. - 89Zr-Bevacizumab PET/CT imaging in NF2 patients
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •In order to be eligible to participate in this study, a subject must meet all
- •of the following criteria:
- •- Patients aged 18 years or older
- •- Confirmed diagnosis of NF2 by revised Manchester criteria (appendix C)
- •- Provided written informed consent
- •- Patients must have measurable disease, defined as at least one VS > 0.4 ml
- •(on volumetric analysis) that can be accurately measured by contrast-enhanced
- •T1-weighted cranial MRI scan.
- •- Eligible and planned for bevacizumab treatment
排除标准
- •A potential subject who meets any of the following criteria will be excluded
- •from participation in this study:
- •- Patients with a contra-indication for PET and MRI, such as pregnancy and
- •metal elements.
- •- Patients with a known allergy to substances used in this study
- •- Concurrend treatment with Everolimus
研究者
相似试验
进行中（未招募）
1 期
89Zr-Bevacizumab PET/CT imaging of vestibular schwannomas for the prediction of bevacizumab treatment effect in patients with symptomatic neurofibromatosis type 2.eurofibromatosis type 2EUCTR2020-000156-35-NLeiden University Medical Center15
已完成
不适用
Everolimage. 89Zr-bevacizumab PET imaging in patients with Renal Cell Carcinoma treated with everolimus; a pilot study.kidney cancer1003836310038430renal cell carcinomaNL-OMON36512niversitair Medisch Centrum Groningen14
已完成
不适用
89Zr-bevacizumab labelled PET imaging in patients with Renal Cell Carcinoma treated with sunitinib or bevacizumab plus interferon; a pilot studyNL-OMON33835niversitair Medisch Centrum Groningen26
招募中
不适用
89Zr-Bevacizumab PET/CT Imaging in NF2 PatientsNeurofibromatosis 2NCT05685836Leiden University Medical Center15
已完成
不适用
89Zr-bevacizumab PET imaging as predictive biomarker for everolimus efficacy in patients with neuroendocrine tumorshormone producing cancerneuroendocrine tumors10014713NL-OMON32849niversitair Medisch Centrum Groningen14